Benford H L, McGowan N W, Helfrich M H, Nuttall M E, Rogers M J
Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK.
Bone. 2001 May;28(5):465-73. doi: 10.1016/s8756-3282(01)00412-4.
Bisphosphonates inhibit osteoclast-mediated bone resorption by mechanisms that have only recently become clear. Whereas nitrogen-containing bisphosphonates affect osteoclast function by preventing protein prenylation (especially geranylgeranylation), non-nitrogen-containing bisphosphonates have a different molecular mechanism of action. In this study, we demonstrate that nitrogen-containing bisphosphonates (risedronate, alendronate, pamidronate, and zoledronic acid) and non-nitrogen-containing bisphosphonates (clodronate and etidronate) cause apoptosis of rabbit osteoclasts, human osteoclastoma-derived osteoclasts, and human osteoclast-like cells generated in cultures of bone marrow in vitro. Osteoclast apoptosis was shown to involve characteristic morphological changes, loss of mitochondrial membrane potential, and the activation of caspase-3-like proteases capable of cleaving peptide substrates with the sequence DEVD. Caspase-3-like activity could be visualized in unfixed, dying osteoclasts and osteoclast-like cells using a cell-permeable, fluorogenic substrate. Bisphosphonate-induced osteoclast apoptosis was dependent on caspase activation, because apoptosis resulting from alendronate, clodronate, or zoledronic acid treatment was suppressed by zVAD-fmk, a broad-range caspase inhibitor, or by SB-281277, a specific isatin sulfonamide inhibitor of caspase-3/-7. Furthermore, caspase-3 (but not caspase-6 or caspase-7) activity could be detected and quantitated in lysates from purified rabbit osteoclasts, whereas the p17 fragment of active caspase-3 could be detected in human osteoclast-like cells by immunofluorescence staining. Caspase-3, therefore, appears to be the major effector caspase activated in osteoclasts by bisphosphonate treatment. Caspase activation and apoptosis induced by nitrogen-containing bisphosphonates are likely to be the consequence of the loss of geranylgeranylated rather than farnesylated proteins, because the ability to cause apoptosis and caspase activation was mimicked by GGTI-298, a specific inhibitor of protein geranylgeranylation, whereas FTI-277, a specific inhibitor of protein farnesylation, had no effect on apoptosis or caspase activity.
双膦酸盐通过直到最近才明确的机制抑制破骨细胞介导的骨吸收。含氮双膦酸盐通过阻止蛋白质异戊二烯化(尤其是香叶基香叶基化)来影响破骨细胞功能,而不含氮的双膦酸盐则有不同的分子作用机制。在本研究中,我们证明含氮双膦酸盐(利塞膦酸盐、阿仑膦酸盐、帕米膦酸盐和唑来膦酸)和不含氮的双膦酸盐(氯膦酸盐和依替膦酸盐)可导致兔破骨细胞、人骨巨细胞瘤来源的破骨细胞以及体外骨髓培养产生的人破骨样细胞发生凋亡。破骨细胞凋亡表现为特征性的形态变化、线粒体膜电位丧失以及能够切割具有DEVD序列的肽底物的类半胱天冬酶-3蛋白酶的激活。使用一种可透过细胞的荧光底物,可在未固定的、即将死亡的破骨细胞和破骨样细胞中观察到类半胱天冬酶-3样活性。双膦酸盐诱导的破骨细胞凋亡依赖于半胱天冬酶激活,因为阿仑膦酸盐、氯膦酸盐或唑来膦酸处理导致的凋亡被广谱半胱天冬酶抑制剂zVAD-fmk或半胱天冬酶-3/-7的特异性异吲哚磺胺抑制剂SB-281277所抑制。此外,在纯化的兔破骨细胞裂解物中可检测和定量类半胱天冬酶-3(而非类半胱天冬酶-6或类半胱天冬酶-7)的活性,而通过免疫荧光染色可在人破骨样细胞中检测到活性半胱天冬酶-3的p17片段。因此,半胱天冬酶-3似乎是双膦酸盐处理在破骨细胞中激活的主要效应半胱天冬酶。含氮双膦酸盐诱导的半胱天冬酶激活和凋亡可能是香叶基香叶基化而非法尼基化蛋白丧失的结果,因为蛋白香叶基香叶基化的特异性抑制剂GGTI-29能够模拟导致凋亡和半胱天冬酶激活的能力,而蛋白法尼基化的特异性抑制剂FTI-277对凋亡或半胱天冬酶活性没有影响。